Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the efficacy of eltrombopag vs rhTPO in complete response
in patients after HSCT in China. This is a post-marketing, interventional, single-center,
double-arm, prospective, open-label, equivalent, randomized controlled study in adult
patients with hematopoietic stem cell transplantation in China. Patients will be recruited
consecutively from the study sites during the enrollment period. The enrolled patients will
be given eltrombopag or rhTPO under the conditions of informed consent and frequent
monitoring according to the clinical guideline.